{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-137119","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2025-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.508207+00:00","generated_at":"2026-05-19T18:43:55.721580+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"All nine proposals approved at NewAmsterdam Pharma 2025 AGM","bullets":["Quorum of 83.6M ordinary shares (74.45%) voted; all nine agenda items passed.","Dutch statutory annual accounts for FY2024 approved: 83.5M for, 5.6K against.","Three non-executive directors (Joustra, McKenna, Gulfo) each elected with >79M for votes.","Michael Davidson reappointed executive director (70.5M for, 9.2M against); James Topper reappointed non-executive.","Share buyback authorization extended (71.4M for, 12.2M against); say-on-pay approved and set for annual frequency."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-137119","json":"https://secwatch.observer/filing/0001193125-25-137119.json","markdown":"https://secwatch.observer/filing/0001193125-25-137119.md","text":"https://secwatch.observer/filing/0001193125-25-137119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525137119/0001193125-25-137119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525137119/d933201d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T18:43:55.721580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}